Elsevier and European Alliance of Associations for Rheumatology announce new partnership

The European Alliance of Associations for Rheumatology (EULAR) announces a new partnership with Elsevier, a global leader in information and analytics, to publish its flagship scientific journal, Annals of the Rheumatic Diseases (ARD). The journal will be hosted on Elsevier’s leading online platform, ScienceDirect, beginning January 2025

“We are delighted that our flagship journal will continue its successful journey with the world's largest publisher and feel that this partnership will equip us ideally for the challenges of the future,” said Professor Daniel Aletaha, EULAR President.

Professor Josef Smolen, ARD Editor-in-Chief, adds: “Authors, researchers and readers can expect a seamless transition while maintaining the journal's high standards and commitment to excellence.”

Originally published in 1939, ARD has always strived for excellence in research advances and novel clinical insights. Thus, it continues to be the leading rheumatology journal publishing high-quality scientific papers, original research, reviews, recommendations, viewpoints, and more. Basic, clinical, and translational scientific research across the inflammatory and non-inflammatory musculoskeletal conditions is part and parcel of this spectrum.

The journal’s authors, reviewers and editors volunteer their time and expertise to contribute and disseminate this important scientific information to the international research community with a hybrid subscription-based model. Its current (2023) Impact Factor of 20.3 places it second overall in the Rheumatology subject category and first among the journals publishing original research advances. The 2023 CiteScore of 35 places it in the #1/73 (99^th percentile) position in the category Medicine/Rheumatology.

“We are very honoured to be chosen as the publishing partner for EULAR. Elsevier is committed to providing EULAR with a trusted platform, addressing customer needs, and providing insight through data analytics. Our collaboration will further support both organisations’ efforts to improve health outcomes”, stated Carl Schwarz, Senior Vice President, Health and Medical Sciences at Elsevier. “ARD is a hugely respected journal in the rheumatology field and will be a great fit with our rheumatology portfolio. We are very proud that EULAR has chosen to partner with us and look forward to helping them and ARD transition to Elsevier,” added Tanya Wheatley, Elsevier’s Executive Publisher for Rheumatology.

About the European Alliance of Associations for Rheumatology (EULAR)

EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야를 선도하는 글로벌 기업입니다. 100년 넘게 과학과 의료의 발전을 뒷받침하며 인류의 더 나은 미래를 위해 노력해왔습니다. 우리는 전 세계 170개국의 대학 및 기업 연구자, 의사, 간호사, 차세대 보건의료 인력과 교육자들이 중요한 업무를 수행할 수 있도록 지원하고 있습니다. 우리는 신뢰할 수 있는 근거 기반의 과학과 의학 콘텐츠에 첨단 인공지능(AI) 기술을 접목한 핵심 인사이트와 혁신적인 솔루션을 제공함으로써, 이들의 더 나은 성과 달성을 돕고자 합니다. 우리는 제품과 조직 문화 전반에 포용성과 지속 가능성의 가치를 반영하고, 함께하는 커뮤니티와의 협력을 통해 이를 실천해 나가고 있습니다. 엘스비어 재단(Elsevier Foundation)은 세계 곳곳에서 연구 및 보건 분야의 협력 사업을 후원하고 있습니다.

엘스비어는 전문가 및 비즈니스 고객을 위한 정보 기반 분석 및 의사결정 도구를 제공하는 글로벌 기업 RELX의 계열사입니다. 자세한 내용은 www.elsevier.com에서 확인하실 수 있으며, SNS @ElsevierConnect를 통해 최신 소식도 실시간으로 받아보실 수 있습니다.